Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Gland-Pharma-Limited"

24 News Found

Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution
Drug Approval | July 24, 2024

Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution

The product is bioequivalent and therapeutically equivalent to the reference listed drug


Gland Pharma receives approval for Edaravone Injection
Drug Approval | May 09, 2024

Gland Pharma receives approval for Edaravone Injection

The product is used to treat amyotrophic lateral sclerosis


Gland Pharma receives USFDA approval for Eribulin Mesylate Injection
Drug Approval | April 07, 2024

Gland Pharma receives USFDA approval for Eribulin Mesylate Injection

The Product is expected to be the first generic approval on the market


Gland Pharma posts Q2 FY24 consolidated PAT at Rs. 194.08 Cr
News | November 07, 2023

Gland Pharma posts Q2 FY24 consolidated PAT at Rs. 194.08 Cr

Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023


Cenexi appoints Jim McPherson as CEO
People | September 20, 2023

Cenexi appoints Jim McPherson as CEO

Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK


Gland Pharma receives 2 observations under 483 for Pashamylaram facility
News | August 28, 2023

Gland Pharma receives 2 observations under 483 for Pashamylaram facility

The company is committed to address the observations and will submit its response to US FDA within the stipulated time


Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr
News | August 08, 2023

Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr

Gland Pharma has reported total income of Rs. 1246.23 crores during the period ended June 30, 2023


Gland Pharma posts Q4 FY23 consolidated PAT at Rs. 78.68 Cr
News | May 19, 2023

Gland Pharma posts Q4 FY23 consolidated PAT at Rs. 78.68 Cr

Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023


USFDA inspection: Zydus Lifesciences and Gland Pharma
Drug Approval | January 28, 2023

USFDA inspection: Zydus Lifesciences and Gland Pharma

The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam